Healthcare investors are beginning to see signs of recovery across several parts of the industry, but not every recovery looks the same. Danaher (NYSE:DHR) is benefiting from improving demand in life sciences after a prolonged post-pandemic slowdown, while Medtronic (NYSE:MDT) is finally beginning to show the results of years of investment in new products and operational execution. Both companies reported encouraging results, but very different factors are driving their recoveries. The question for investors is which recovery story offers the greater long-term upside.
Bull case
The strongest argument supporting Medtronic (NYSE:MDT) is that its turnaround is no longer being driven by cost controls alone. The company’s latest results suggest its newer growth platforms are beginning to contribute meaningfully to revenue. The company reported its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, with adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. The trends suggest that the company is exhibiting continued operational rigor and building momentum in its highest growth opportunities, including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS.
Furthermore, Medtronic’s (NYSE:MDT) cardiac segment is emerging as one of the most prominent growth drivers for the company, as the Cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth. That is significant for investors because cardiac devices remain one of the company’s highest-margin and fastest-growing businesses.
Danaher’s story, however, depends much more on improving customer spending across its Life Sciences business, which delivered its strongest performance in several years. Although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained strong, which includes consumables and equipment necessary to make biologic drugs.
Danaher Corporation (NYSE:DHR) also stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters. This suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth.
Bear Case
Although Medtronic’s (NYSE:MDT) recovery is encouraging, much of its recent momentum has come from a relatively small number of faster-growing platforms. Investors will likely want to see stronger growth become more broadly distributed across the company’s portfolio before concluding that the turnaround has fully taken hold. This concern is further amplified as competition remains intense in cardiovascular devices and robotic surgery, especially from peers like Intuitive Surgical and Boston Scientific.
On the other hand, Danaher Corporation (NYSE:DHR) reported weaker-than-expected revenue in its biotechnology business and cut its full-year core revenue growth outlook. The company cut the upper end of its core revenue growth outlook range to 4% from 6% for the year, and maintained the lower end at 3%, primarily to take into account the effects of the weaker respiratory testing revenue. That suggests the recovery remains uneven across Danaher’s (NYSE:DHR) portfolio. While life sciences spending continues improving, weakness in biotechnology and respiratory testing indicates not every end market has recovered at the same pace.
What Do Hedge Funds Say?
Institutional positioning provides additional context for the investment thesis. According to Insider Monkey’s database tracking 1,022 hedge funds, both Danaher (NYSE:DHR) and Medtronic (NYSE:MDT) saw a decline in hedge fund ownership between the fourth quarter of 2025 and the first quarter of 2026. Danaher (NYSE:DHR) remained the more widely held stock, with hedge fund ownership falling from 125 funds to 110, while Medtronic’s (NYSE:MDT) ownership declined more modestly from 63 funds to 60.
Although Danaher (NYSE:DHR) continues to enjoy stronger institutional ownership overall, the sharper decline suggests some hedge funds became more cautious toward the stock following its guidance revision, whereas positioning in Medtronic (NYSE:MDT) remained comparatively stable despite its ongoing turnaround.
Which Recovery Looks More Durable?
The two companies are recovering for different reasons. Medtronic’s (NYSE:MDT) growth is increasingly being driven by internal execution, new product launches, and improving operational performance. Danaher (NYSE:DHR), meanwhile, depends more heavily on an external recovery in pharmaceutical and biotechnology spending. If life sciences demand continues strengthening, Danaher (NYSE:DHR) could benefit significantly. However, if that recovery stalls, Medtronic’s (NYSE:MDT) company-specific growth initiatives may prove more resilient.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center